Skip to main content

Increasing Knowledge to Improve Patient Outcomes in Multiple Myeloma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding practice-changing strategies for improved patient outcomes in multiple myeloma.   Multiple myeloma is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. Approximately 35,780 new cases of multiple myeloma are expected to occur in the United States this year, and around 12,540 people are likely to die of...

Continue reading

Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD

Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and share...

Continue reading

Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP

Oncology Data Advisor™ · Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care s...

Continue reading

Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP

Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care strategies since recording. Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital resource for the multidiscipl...

Continue reading

Significant Knowledge Gains for the Diagnosis and Management of T-Cell Lymphoma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding the diagnosis and evidence-based management of T-cell lymphoma (TCL). T-cell lymphoma is an uncommon subtype accounting for approximately 7% of all cases of non-Hodgkin lymphoma in the United States. Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL ...

Continue reading

Improved Understanding of Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding precision medicine in BRAF V600E­–mutant metastatic colorectal cancer (CRC).   Colorectal cancer is the second leading cause of cancer death among men and women in the United States, with the American Cancer Society estimating that there will be 106,970 new cases of colon cancer, 46,050 new cases of rectal cancer, and 52,550 deaths due to colorectal cancer in 2023 alon...

Continue reading

Expert Perspectives in the Management of Triple-Negative Breast Cancer: a Webinar Preview With Sara Tolaney, MD, MPH

i3 Health recently hosted Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on the i3 Health website. In this video interview, Dr. Tolaney shares a preview of the important topics discussed in the activity, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Oncology Data Advisor:...

Continue reading

Confronting Knowledge Gaps in Rare Hematologic Malignancies

In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians regarding hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM).  According to the Leukemia and Lymphoma Soc...

Continue reading

Additional Advances in Immune Thrombocytopenia Research and Clinical Trials With Allison Imahiyerobo, APN

Oncology Data Advisor™ · Additional Advances in Immune Thrombocytopenia Research and Clinical Trials In 2022, Allison Imahiyerobo, an Advanced Practice Nurse at the Englewood Health Physician Network in New Jersey, led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity with i3 Health, New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia. A year later, Ms. Imahiyerobo sat down with Oncology Data Advis...

Continue reading

Assessing Proficiency in Squamous Non–Small Cell Lung Cancer Management

i3 Health recently provided an online continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity that has challenged the health care team's proficiency in managing metastatic squamous non–small cell lung cancer (NSCLC). Lung cancer is the second most common cancer in the United States between both men and women, with the American Cancer Society estimating a total of 238,340 new cases being diagnosed and 127,070 deaths occurring throughout 2023. Appr...

Continue reading

Staying Up to Date on Endometrial Cancer With Ritu Salani, MD

Cancer of the uterine corpus, also called endometrial cancer, is the most common cancer of the female genital tract, with the American Cancer Society estimating that there will be 65,950 new diagnoses and 12,550 fatal cases in the United States in 2022. In this interview, Ritu Salani, MD, Director of the Division of Gynecologic Oncology at the University of California, Los Angeles (UCLA) Health, touches base on a recent activity she led, Emerging Checkpoint Inhibitor-Based Strategies for Advanced Endometrial Cancer. In addition, she discusses updates since recording the activity and why it's important for health care professionals to participate in staying up to date with the evolving landscape of endometrial cancer treatment options.  

Continue reading

New and Exciting Directions in Leukemia Research, Fellows Forum With Sunil Iyer, MD

Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Sunil Iyer, Chief Hematology/Oncology Fellow at the University of Miami, Florida, discusses his leukemia research, exciting new treatment directions, and what to look forward to in the next several years regarding leukemia research.  Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows For...

Continue reading

Knowledge Gains for Immunotherapeutic Strategies in Cervical Cancer

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity, which was presented as both a Video Viewpoint Strategy Session and a podcast, provided significant gains in proficiency amongst the health care professionals who participated....

Continue reading

Educational Advancements Made in Treatment of Merkel Cell Carcinoma

i3 Health has provided a continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma, that enabled the health care team to acquire significant gains in proficiency and knowledge for treating their patients with Merkel cell carcinoma (MCC). Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromi...

Continue reading

Enhancing Treatment and Patient-Care Proficiency in Multiple Myeloma

i3 Health has provided a nursing continuing professional development (NCPD)–approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, during which the health care team was challenged to address knowledge gaps experienced in this field. Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. The American Cancer Society approximates 35,730 new cases of MM to be...

Continue reading

Addressing Knowledge Gaps in Management of Tumor Lysis Syndrome

Recently, i3 Health provided a continuing medical education/nursing continuing professional development/continuing pharmacy education (CME/NCPD/CPE)–approved activity, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies, during which clinicians' knowledge gaps were challenged and knowledge gains were achieved. Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor c...

Continue reading

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. 

Continue reading

Knowledge Gained for Treatment of Metastatic Hormone-Sensitive Prostate Cancer

An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnosed, with 34,500 of these cases resulting in death. Most patients with mHSPC present with relapse after local treatment, while approximately 5% of all p...

Continue reading

Increasing Expertise for Treatment of Non-Hodgkin Lymphoma

An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American Cancer Society estimated that 80,470 new diagnoses of NHL will occur in 2022, with 20,250 resulting in death. Aggressive subtypes, including diffuse ...

Continue reading

Addressing Knowledge Gaps in Treatment Strategies for Cholangiocarcinoma

An educational activity provided by i3 Health has addressed knowledge gaps and produced expertise pertaining to treatment strategies for cholangiocarcinoma. Cholangiocarcinoma, also known as bile duct cancer, is a rare malignancy originating in the epithelium of the bile duct. The American Cancer Society estimates that 8,000 cases of bile duct cancer are diagnosed each year, but it is acknowledged that this number could be higher due to the cancer being hard to diagnose and the potential for mis...

Continue reading